Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature

Background: Ovarian cancer has a low incidence, but high mortality due to a habitual diagnosis in advanced cancer stages. Currently, used biomarkers have good sensitivity, but low specificity. Aim: To determine the usefulness of the biomarkers and algorithms used up to now in the screening, diagnosi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Miguel Ángel Elorriaga, José Luis Neyro, Jon Mieza, Ignacio Cristóbal, Antoni Llueca
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	biomarkers tumour markers CA125 HE4 antigen algorithms screening Medicine R
Acceso en línea:	https://doaj.org/article/fe2801449599427b8c0292e608706228
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fe2801449599427b8c0292e608706228
record_format	dspace
spelling	oai:doaj.org-article:fe2801449599427b8c0292e6087062282021-11-25T18:07:19ZBiomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature10.3390/jpm111111152075-4426https://doaj.org/article/fe2801449599427b8c0292e6087062282021-10-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1115https://doaj.org/toc/2075-4426Background: Ovarian cancer has a low incidence, but high mortality due to a habitual diagnosis in advanced cancer stages. Currently, used biomarkers have good sensitivity, but low specificity. Aim: To determine the usefulness of the biomarkers and algorithms used up to now in the screening, diagnosis, response to treatments and identification of recurrence in patients with ovarian masses. Methodology: Systematic search of publications in English in the Medline-PubMed database with the terms: “biomarkers”, “tumour”, “tumour biomarkers”, “marker”, “tumour marker”, “ovarian cancer”, “ovarian”, “Neoplasms”, “cancer”, CA-125 Antigen; Human Epididymis-specific Protein E4; Risk of Malignancy Index (RMI); Risk of Ovarian Malignancy Algorithm (ROMA); Ovarian Neoplasms. Original articles, clinical trials, reviews, systematic reviews and meta-analyses, published between January 2000 and November 2020, were selected to determine the usefulness (among others) of CA 125 and HE4 antigen in ovarian cancer. Results: Finally, 39 transcendental publications were selected to write this article to determine the usefulness of tumour markers and algorithms in ovarian cancer. Conclusions: The usefulness of the tumour markers antigen CA125 and antigen HE4 individually or as a basis for decision-making algorithms has low specificity; however, there is little evidence that confirms their usefulness as markers in ovarian cancer screening.Miguel Ángel ElorriagaJosé Luis NeyroJon MiezaIgnacio CristóbalAntoni LluecaMDPI AGarticlebiomarkerstumour markersCA125HE4 antigenalgorithmsscreeningMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1115, p 1115 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biomarkers tumour markers CA125 HE4 antigen algorithms screening Medicine R
spellingShingle	biomarkers tumour markers CA125 HE4 antigen algorithms screening Medicine R Miguel Ángel Elorriaga José Luis Neyro Jon Mieza Ignacio Cristóbal Antoni Llueca Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
description	Background: Ovarian cancer has a low incidence, but high mortality due to a habitual diagnosis in advanced cancer stages. Currently, used biomarkers have good sensitivity, but low specificity. Aim: To determine the usefulness of the biomarkers and algorithms used up to now in the screening, diagnosis, response to treatments and identification of recurrence in patients with ovarian masses. Methodology: Systematic search of publications in English in the Medline-PubMed database with the terms: “biomarkers”, “tumour”, “tumour biomarkers”, “marker”, “tumour marker”, “ovarian cancer”, “ovarian”, “Neoplasms”, “cancer”, CA-125 Antigen; Human Epididymis-specific Protein E4; Risk of Malignancy Index (RMI); Risk of Ovarian Malignancy Algorithm (ROMA); Ovarian Neoplasms. Original articles, clinical trials, reviews, systematic reviews and meta-analyses, published between January 2000 and November 2020, were selected to determine the usefulness (among others) of CA 125 and HE4 antigen in ovarian cancer. Results: Finally, 39 transcendental publications were selected to write this article to determine the usefulness of tumour markers and algorithms in ovarian cancer. Conclusions: The usefulness of the tumour markers antigen CA125 and antigen HE4 individually or as a basis for decision-making algorithms has low specificity; however, there is little evidence that confirms their usefulness as markers in ovarian cancer screening.
format	article
author	Miguel Ángel Elorriaga José Luis Neyro Jon Mieza Ignacio Cristóbal Antoni Llueca
author_facet	Miguel Ángel Elorriaga José Luis Neyro Jon Mieza Ignacio Cristóbal Antoni Llueca
author_sort	Miguel Ángel Elorriaga
title	Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
title_short	Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
title_full	Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
title_fullStr	Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
title_full_unstemmed	Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature
title_sort	biomarkers in ovarian pathology: from screening to diagnosis. review of the literature
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/fe2801449599427b8c0292e608706228
work_keys_str_mv	AT miguelangelelorriaga biomarkersinovarianpathologyfromscreeningtodiagnosisreviewoftheliterature AT joseluisneyro biomarkersinovarianpathologyfromscreeningtodiagnosisreviewoftheliterature AT jonmieza biomarkersinovarianpathologyfromscreeningtodiagnosisreviewoftheliterature AT ignaciocristobal biomarkersinovarianpathologyfromscreeningtodiagnosisreviewoftheliterature AT antonillueca biomarkersinovarianpathologyfromscreeningtodiagnosisreviewoftheliterature
_version_	1718411658858070016

Biomarkers in Ovarian Pathology: From Screening to Diagnosis. Review of the Literature

Ejemplares similares